KEM® Biomarker case study presented at EACR-23 this week showed that prognostic signatures generated by KEM® Biomarker have better or similar performances to other classification methods in terms of sensitivity and specificity while having significantly lower number of features in the models.
23rd Biennial Congress of the European Association for Cancer Research. From Basic Research to Personalised Cancer Treatment, 5-8 July 2014, Munich, Germany.
“P667: Shorter multimarker signatures: a new tool to facilitate cancer diagnosis”, M.P. Schneider, N. Jullian, M. Afshar, M. Guergova-Kuras, Tersan Pharmaceuticals Ltd.